Back to search
FDAFDA · Food and drugs·Recall number D-0435-2023

Heparin Sodium Injection, USP, 20,000 USP units per mL, 25 x 1 mL Multi-Dose Vials, Rx Only, For Intravenous or Subcutaneous Use, Mfd. for: Sagent Pharmaceuticals, Schaumburg, IL 60195; Made in India, NDC carton: 25021-404-01

Published March 15, 2023 · Recall initiated: February 28, 2023

Summary

FDA records drug Class II recall D-0435-2023, published March 15, 2023 and initiated February 28, 2023. Recalling firm: Sagent Pharmaceuticals Inc; Status: Terminated; Reported quantity: 28,875 vials; Lot: Lot#: WP201, Exp 2/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Not elsewhere classified

What to do

Voluntary: Firm initiated · Letter

Get an email if HEPARIN SODIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
HEPARIN SODIUM
Manufacturer
Sagent Pharmaceuticals Inc
Distributor
USA Nationwide
Lot
Lot#: WP201, Exp 2/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Heparin Sodium Injection, USP, 20,000 USP units per mL, 25 x 1 mL Multi-Dose Vials, Rx Only, For Intravenous or Subcutaneous Use, Mfd. for: Sagent Pharmaceuticals, Schaumburg, IL 60195; Made in India, NDC carton: 25021-404-01 recalled?

Yes. FDA published recall D-0435-2023 on March 15, 2023. Reported hazard: Labeling: Not elsewhere classified

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: HEPARIN SODIUM.